Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Analysis: Older men treated for early prostate cancer live longer than those not treated

14.12.2006
Study of SEER-Medicare Data published in Dec. 13th Issue of JAMA

An analysis of Surveillance, Epidemiology and End Results (SEER)-Medicare records for 44,630 older men suggests surgery or radiation therapy for early-stage prostate cancer increased the lifespan of men between 65 and 80 years old compared to observation, sometimes known as "watch and wait." Published in the Dec. 13 issue of Journal of the American Medical Association, the study supported a benefit of treatment even for men whose disease had a low risk of spreading, and even if they were elderly men (75 to 80 years old).

"Studies have shown that low- and intermediate-grade prostate cancers may grow slowly, and many patients may never suffer complications from their disease. This makes decisions regarding treatment complicated for patients and their families," said lead author Yu-Ning Wong, M.D., a medical oncologist at Fox Chase Cancer Center who authored the study with colleagues at the University of Pennsylvania. "In our study, we looked back at existing data that tracked long term outcomes of elderly men whose cancer was at low and intermediate risk of spreading. After accounting for all of the observed differences between the groups, we found that men who had either a radical prostatectomy or radiation therapy within six months of their prostate cancer diagnosis were 30 percent less likely to die than those who did not undergo treatment during this time period," she said.

Researchers confined the study sample to men with small tumors (clinically designated as T1 or T2) with well-differentiated (corresponding Gleason score 2 to 4) or moderately differentiated (corresponding Gleason score 5 to 7) prostate cancers, who were diagnosed between 1991 and 1999.

Of the 44,630 patients included in the study, 12,608 (28.3 percent) were not treated while 32,022 (71.8 percent) were actively treated. In the treatment group, 88 percent lived five years or longer and 66 percent lived 10 years or longer. In the non-treatment group, 78 percent lived five years or longer and 51 percent lived 10 years or longer. The benefit of treatment was still present after adjusting for differences between the treatment and non-treatment groups, including patient demographics and tumor characteristics.

Since the study was a retrospective analysis of existing data (observational) rather than a randomized controlled trial, the authors noted that treatment and non-treatment groups may differ in measured and unmeasured ways that are associated with differences in survival.

"Observational studies such as ours should be interpreted with caution, since men who were offered treatment, or specific types of treatment, may have been ‘healthier' than men who were not offered treatment, which raises the possibility that the treatment benefit may due to the selection of healthier men," Wong noted. "We performed extensive statistical adjustments to account for these differences and still found that treatment was associated with longer survival."

Wong emphasized that observation is a reasonable choice for many men since some prostate cancers grow slowly. Studies have shown that in recent years, only between 7 and 17 percent of men in the U.S. with low-risk localized prostate cancer choose observation rather than treatment.

Longer survival alone is not the only factor in choosing treatment over observation, Wong pointed out. "The risks of treatment have decreased as options have improved including more targeted radiation therapy that reduce side effects and less invasive surgical techniques, but both may be associated with bowel, bladder and sexual dysfunction. Patients should talk to their doctors about their risks of side effects associated with radiation, surgery and observation before making treatment decisions."

"Our study is just one piece of an extraordinarily complex puzzle, and many other researchers are examining different aspects of prostate cancer biology and treatment. Patients should consider enrolling in clinical trials and other research protocols to help us better understand how prostate cancer grows and which patients most likely to benefit." Wong concluded.

Karen Mallet | EurekAlert!
Further information:
http://www.fccc.edu

More articles from Studies and Analyses:

nachricht Study relating to materials testing Detecting damages in non-magnetic steel through magnetism
23.07.2018 | Technische Universität Kaiserslautern

nachricht Innovative genetic tests for children with developmental disorders and epilepsy
11.07.2018 | Christian-Albrechts-Universität zu Kiel

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>